BioSpace News Archive

For $150 million upfront, Sanofi will gain access to Maze’s lead asset MZE001, which inhibits the GYS1 protein in the rare genetic disorder.

Scientists must act differently than other professionals to build a successful personal brand on social media. Check out our comprehensive guide to get started.

The partnership with Chinese biotech Cellular Biomedicine Group will cost J&J $245 million upfront and give it access to two differentiated CAR-T therapies for diffuse large B-cell lymphoma.

In addition to promoting their brands, companies say their funding initiatives give them access to the expertise of top researchers and contribute to society.

argenx announced that members of management will participate in a fireside chat at the BofA Securities 2023 Health Care Conference on Tuesday, May 9, 2023, at 8:00 a.m. P.T. in Las Vegas, NV.

Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces that the US Food and Drug Administration has cleared its Investigational New Drug application for its second-generation DSR product for the treatment of congestive heart failure.

Hyloris Pharmaceuticals SA announces the US Food & Drug Administration has set 17 October 2023 as the date by which it expects to respond to the application regarding Maxigesic® IV.

ObsEva SA, a biopharmaceutical company developing novel therapies for women’s health, announced that Fabien de Ladonchamps has been appointed Chief Executive Officer effective May 1, 2023.

Verona Pharma plc announces 12 abstracts, including a mini symposium, and a clinical trials symposium, on additional analyses from its successful Phase 3 ENHANCE studies with ensifentrine for the treatment of chronic obstructive pulmonary disease have been accepted by the American Thoracic Society International Conference 2023.

OKYO Pharma Limited is pleased to announce that the first patient has been screened for its phase 2, multi-center, randomized, double–blinded, placebo-controlled trial, evaluating the efficacy and safety of OK-101 ophthalmic solution in subjects with dry eye disease.